Discover Community Create You

Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Article

A phase I study of vistusertib (dual mTORC1/2 inhibitor) in patients with previously treated glioblastoma multiforme: a CCTG study

9 Nov 2019

Abstract excerpt

No abstract is available from the source.

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to Cancer, Hypoxia, and Metabolism
Share to Glioma Diagnosis and Treatment
Share to Renal cell carcinoma treatment

Source

Methodology Data sources Editorial policy Privacy About Contact Helena Bioinformatics

Identifiers

PMID: 31707687
DOI: 10.1007/s10637-019-00875-4

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 7 Sept 2026.

Related research

Semantic proximity does not establish scientific evidence.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

A phase I study of vistusertib (dual mTORC1/2 inhibitor) in patients with previously treated glioblastoma multiforme: a CCTG studyPMID 31707687Read ↗

A phase II study of the Ras-MAPK signaling pathway inhibitor TLN-4601 in patients with glioblastoma at first progressionSemantic proximity Read ↗

Targeting mTOR in Glioblastoma: Rationale and Preclinical/Clinical EvidenceSemantic proximity Read ↗

mTOR-Rictor-EGFR axis in oncogenesis and diagnosis of glioblastoma multiformeSemantic proximity Read ↗

Efficacy of rapamycin against glioblastoma cancer stem cellsSemantic proximity Read ↗

Dual mTORC1/2 blockade inhibits glioblastoma brain tumor initiating cells in vitro and in vivo and synergizes with temozolomide to increase orthotopic xenograft survival.Semantic proximity Read ↗

Overcoming standard-of-care resistance in glioblastoma using nanoparticle-based drug delivery targeting the autophagy pathwaySemantic proximity Read ↗

mTOR inhibition: a double-edged sword in patients with COVID-19?Semantic proximity Read ↗

BMS345541 is predicted as a repurposed drug for the treatment of TMZ-resistant Glioblastoma using target gene expression and virtual drug screeningSemantic proximity Read ↗

Effects of Combination Therapy of a CDK4/6 and MEK Inhibitor in Diffuse Midline Glioma Preclinical ModelsSemantic proximity Read ↗

MGMT in TMZ-based glioma therapy: Multifaceted insights and clinical trial perspectivesSemantic proximity Read ↗

TP53 mutated glioblastoma stem-like cell cultures are sensitive to dual mTORC1/2 inhibition while resistance in TP53 wild type cultures can be overcome by combined inhibition of mTORC1/2 and Bcl-2.Semantic proximity Read ↗

PP242 Counteracts Glioblastoma Cell Proliferation, Migration, Invasiveness and Stemness Properties by Inhibiting mTORC2/AKTSemantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.